Anixa Biosciences (ANIX)

• Market cap: $98.2M
• 1 day: 0.66%
• 5 days: 14.23%
• 1 month: 0.99%
• 3 months: 20.55%
• 6 months: -11.59%
• Year to date: 28.69%
• 1 year: -13.11%
• 5 years: 70.39%
• 10 years: -19.74%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Anixa Biosciences Inc a cancer-focused biotechnology company, develops vaccines and therapies that are focused on critical unmet needs in oncology. The company is developing both diagnostics and therapeutics to detect cancer early, which is curable, and to treat those afflicted once diagnosed. Its segment includes CAR-T Therapeutics; Cancer Vaccines; Anti-Viral Therapeutics and others.

Employees: 5

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

224% more call options, than puts

Call options by funds: $201K | Put options by funds: $62K

38% more repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 8

11% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 9

0.71% more ownership

Funds ownership: 17.45% [Q3] → 18.16% (+0.71%) [Q4]

2% less funds holding

Funds holding: 58 [Q3] → 57 (-1) [Q4]

23% less capital invested

Capital invested by funds: $17.6M [Q3] → $13.6M (-$4.01M) [Q4]

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $7 130% upside
• Avg. target: $8.50 179% upside
• High target: $10 228% upside

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Yi Chen 38% 1-year accuracy 61 / 162 met price target	130% upside $7	Buy Reiterated	18 Feb 2025
D. Boral Capital Jason Kolbert 27% 1-year accuracy 78 / 286 met price target	228% upside $10	Buy Maintained	22 Jan 2025